<DOC>
	<DOCNO>NCT02862067</DOCNO>
	<brief_summary>To determine effect SGLT2 inhibition empagliflozin cardio-respiratory fitness patient systolic heart failure .</brief_summary>
	<brief_title>SGLT2 Inhibition Diabetes Heart Failure</brief_title>
	<detailed_description>The investigator hypothesize Sodium-GLucose coTransporters ( SGLT ) -2 inhibition improve cardio-respiratory fitness ( CRF ) patient systolic heart failure . Participants treat SGLT2 inhibitor Empagliflozin standard care undergo assessment describe . The investigator measure CRF validate cardiopulmonary exercise test baseline 4 week treatment receive standard care , determine whether SGLT2 inhibition improve cardio-respiratory fitness assess change peak oxygen consumption ( VO2 ) ( mL/kg/min ) minute ventilation ( VE ) /carbon dioxide production ( VCO2 ) slope , powerful independent clinical predictor mortality HF .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>Confirmed clinical diagnosis stable HF ( NYHA class IIIII ) maximally tolerate HF medical regimen include angiotensininhibitors , betaadrenergic blocker , loop diuretic Reduced left ventricular systolic function ( LVEF &lt; 50 % ) document prior 12 month Poorly control T2DM ( HbA1c level 7.0 % 10.0 % treatment regimen include insulin , 6.5 % 10.0 % insulin treatment regimen ) 18 year old old . Type I diabetes ; Type II diabetes episode severe hypoglycemia &lt; 50 mg/dl history , frequent change antidiabetic regimen class past 3 month prior episode diabetic ketoacidosis ( time ) ; Open label treatment SGLT2 inhibitor ( within past month ) ; Treatment thiazolidinedione ( within past month ) , may induce volume sodium retention ; Chronic Kidney Disease ( GFR &lt; 45 ml/kg*min ) ; Uncontrolled thyroid dysfunction ( TSH &lt; 0.4 &gt; 4.5 mcIU/ml ) ; Pregnancy childbearing potential ; Active recent ( within 2 week ) genital/urinal infection ; Concomitant condition treatment would affect completion interpretation study include physical inability walk run treadmill decompensated HF ( edema , NYHA class IV ) , significant ischemic heart disease , angina , arterial hypotension ( BP systolic &lt; 90 mmHg ) , orthostatic arterial hypotension , arterial hypertension ( rest BP systolic &gt; 160 mmHg ) , atrial fibrillation rapid ventricular response , severe valvular disease , severe chronic obstructive restrictive pulmonary disease , moderate severe anemia ( Hgb &lt; 10 g/dl ) ; Abnormal BP heart rate response , angina ECG change ( ischemia arrhy thmias ) occur baseline cardiopulmonary exercise testing ; Chronic use oral corticosteroid ; Inability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SGLT2</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>systolic heart failure</keyword>
	<keyword>heart failure reduce ejection fraction</keyword>
</DOC>